Table 1 Summary of the HHM cases in breast cancer patients without bone metastasis
Case | Age at onset | Sex | Stage | Metastatic organ | DFI (m) | Subtype | From symptomatic onset to admission (m) | Maximum Ca (mg/dL) | Symptoms due to hypercalcemia | Treatment | Treatment duration (m) | Response to anticancer treatment | Outcome | References |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 53 | F | Rec | Lung* Liver | 120 | ER + HER2 + | < 1 | 17.1 | Yes | Hydration/calcitonin/bisphosphonates/furosemide | 4 | Poor | Dead | This report |
2 | 46 | F | Rec | Liver | 32 | ER + HER2– | < 1 | 15.8 | Yes | Hydration/calcitonin/bisphosphonates/furosemide | < 1 | Poor | Dead | This report |
3 | 66 | F | Rec | Lung* Liver | 12 | ER + HER2– | 2 | 15.0 | Yes | Hydration/calcitonin/bisphosphonates/furosemide | 10 | Good | Alive | This report |
4 | 38 | F | Rec | Lung | 9 | ER– | 1 | 14.2 | Yes | Hydration/calcitonin/glucocorticoids | 1 | Poor | Dead | [5] |
5 | 49 | F | Rec | Liver | 33 | ER + HER2– | 1 | 15.8 | Yes | Calcitonin/bisphosphonates/glucocorticoids | 8 | Good | Alive | [6] |
6 | 46 | F | IV | Liver LN | NA | ER– HER2 + | < 1 | 19.4 | Yes | Hydration/calcitonin/bisphosphonates/glucocorticoids | 14 | Good | Alive | [7] |
7 | 37 | F | IV | Lung | NA | ER + HER2– | < 1 | 21.2 | Yes | Hydration/calcitonin/bisphosphonates | 13 | Good | Alive | [8] |
8 | 68 | F | III B | LN | NA | ER + HER2– | NA | 12.3 | No | Hydration/calcitonin | 6 | Good (surgery) | Alive | [9] |